Decision Resources Research Reports

Title	Published	Price
Biologics Pipelines: Who Has the Next Promising Recombinant Proteins? By: Decision Resources Introduction Therapeutic recombinant protein development has added a broad range of new products to the pharmaceutical armamentarium and led to a burgeoning biotechnology industry that is growing much faster than the small molecule- \| more...	4/22/2008	$1,112.50
Targeting Kinases for Drug Discovery By: Decision Resources Introduction Protein kinases—intracellular enzymes that modulate cellular functions—play a pivotal role in the signal transduction processes that regulate many key biological processes. Abnormalities in these signal transduction pathways are implicated in the \| more...	4/17/2008	$1,125.00
Harnessing Biomarker Research in Academic Institutions for Use in Industry By: Decision Resources Introduction Academic research institutions are a rich source of technology for commercial biomarker development. Some of today’s most dynamic biomarker discoveries originated from academic-industrial relationships, resulting in millions of dollars for universities and billions \| more...	4/3/2008	$1,669.00
Obesity By: Decision Resources A therapy that is more effective than orlistat at inducing weight loss for the treatment of obesity. Using Target Product Profiles in Your Market Strategy Our Target Product Profiles qualitatively \| more...	3/30/2008	$5,625.00
Dyslipidemia By: Decision Resources An HDL-raising drug that has a lower discontinuation rate than extended-release (ER) niacin for the treatment of dyslipidemia. Using Target Product Profiles in Your Market Strategy Our Target Product Profiles \| more...	3/30/2008	$5,625.00
Hepatitis C Virus By: Decision Resources A protease inhibitor that has a significantly higher SVR rate than current therapies among treatment-nonresponders when used as a second-line therapy in combination with a long-acting IFN-alpha and ribavirin for the treatment of HCV. \| more...	3/30/2008	$5,625.00
Community-Acquired Pneumonia By: Decision Resources An antibiotic with targeted activity against respiratory pathogens that does not affect bowel flora for the treatment of community-acquired pneumonia. Using Target Product Profiles in Your Market Strategy Our Target \| more...	3/30/2008	$5,625.00
Rheumatoid Arthritis By: Decision Resources A therapy that is combined with methotrexate that can induce remission (Disease Activity Score in 28 joints [DAS28] \| more...	3/30/2008	$5,625.00
Psoriasis By: Decision Resources A systemic agent that induces 75% improvement in PASI scores at 12 weeks in at least 30% more patients than etanercept for the treatment of psoriasis. Using Target Product Profiles in Your Market \| more...	3/30/2008	$5,625.00
Crohn's Disease By: Decision Resources A parenterally dosed therapy that induces closure and healing of fistulas in a greater percentage of Crohn’s disease patients than infliximab does. Using Target Product Profiles in Your Market Strategy \| more...	3/30/2008	$5,625.00
Asthma By: Decision Resources An inhaled drug with a novel mechanism of action for the treatment of persistent asthma. Using Target Product Profiles in Your Market Strategy Our Target Product Profiles qualitatively predict the market \| more...	3/30/2008	$5,625.00
Urge Urinary Incontinence By: Decision Resources A drug treatment offering a greater reduction in the number of UUI episodes per week than extended-release tolterodine for the treatment of urge urinary incontinence. Using Target Product Profiles in Your Market Strategy \| more...	3/30/2008	$5,625.00
Diabetic Retinopathy By: Decision Resources A therapy that is more effective than bevacizumab in improving visual acuity when used as an adjunct to laser photocoagulation therapy for the treatment of diabetic retinopathy. Using Target Product Profiles in Your \| more...	3/30/2008	$5,625.00
Diabetic Neuropathy By: Decision Resources An agent offering pain relief superior to that of pregabalin. Using Target Product Profiles in Your Market Strategy Our Target Product Profiles qualitatively predict the market potential of a drug \| more...	3/30/2008	$5,625.00
Diabetic Nephropathy By: Decision Resources A therapy that is more effective than irbesartan in inducing regression from microalbuminuria to normoalbuminuria for the treatment of diabetic nephropathy. Using Target Product Profiles in Your Market Strategy Our \| more...	3/30/2008	$5,625.00
Benign Prostatic Hyperplasia By: Decision Resources A drug with lower incidence of sexual side effects than tamsulosin for the treatment of benign prostatic hyperplasia. Using Target Product Profiles in Your Market Strategy Our Target Product \| more...	3/30/2008	$5,625.00
Mild Cognitive Impairment By: Decision Resources A therapy that improves ADAS-cog score from baseline at 12 months for the treatment of mild cognitive impairment. Using Target Product Profiles in Your Market Strategy Our Target Product Profiles \| more...	3/30/2008	$5,625.00
Major Depression By: Decision Resources A therapy that can prevent recurrence of major depressive disorder in a greater percentage of patients than venlafaxine XR does at one year. Using Target Product Profiles in Your Market Strategy \| more...	3/30/2008	$5,625.00
Insomnia By: Decision Resources A hypnotic that is free of next-day residual effects for the treatment of insomnia. Using Target Product Profiles in Your Market Strategy Our Target Product Profiles qualitatively predict the market \| more...	3/30/2008	$5,625.00
Bipolar Disorder By: Decision Resources A therapy that carries a lower risk of weight gain than quetiapine and has both antimanic and antidepressant effects for the treatment of bipolar disorder. Using Target Product Profiles in Your Market Strategy \| more...	3/30/2008	$5,625.00
Alzheimer's Disease (Moderate to Severe) By: Decision Resources A symptomatic therapy with efficacy greater than that of memantine as measured by the Severe Impairment Battery (SIB) at 28 weeks for the treatment of moderate-to-severe AD. Using Target Product Profiles in Your \| more...	3/30/2008	$5,625.00
Acute Ischemic Stroke By: Decision Resources IV reperfusion agent approved for use within six hours of acute ischemic stroke. Using Target Product Profiles in Your Market Strategy Our Target Product Profiles qualitatively predict the market potential \| more...	3/30/2008	$5,625.00
Post-Myocardial Infarction By: Decision Resources A therapy that, combined with aspirin, causes less major bleeding than the combination of clopidogrel and aspirin for the treatment of postmyocardial infarction. Using Target Product Profiles in Your Market Strategy \| more...	3/30/2008	$5,625.00
Peripheral Arterial Disease By: Decision Resources A therapy that reduces the need for revascularization by more than 20% for the treatment of peripheral arterial disease (intermittent claudication). Using Target Product Profiles in Your Market Strategy Our \| more...	3/30/2008	$5,625.00
Hypertension By: Decision Resources An oral drug that reduces left ventricular mass index significantly more than valsartan Using Target Product Profiles in Your Market Strategy Our Target Product Profiles qualitatively predict the market potential \| more...	3/30/2008	$5,625.00
Title	Published	Price

< prev 1 2 3 4 5 6 7 8 9 10 next >

Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2009, All Rights Reserved, MarketResearch.com
11/23/2009 - 2